Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to…

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization…

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9

The companies enter into a…

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD

Minoryx‘s Marketing Authorization Application for…

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Minoryx raises €51 million to…

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

Presentation highlights reduction in cerebral…

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Minoryx publishes mechanism of action…

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study…

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from…